My­ovant beefs up da­ta pack­age in NDA #3, boost­ing its case for longterm dos­ing of Pfiz­er-part­nered re­l­u­golix

When Pfiz­er hand­ed over $650 mil­lion in cash to part­ner on My­ovant’s re­l­u­golix, the phar­ma gi­ant made clear that the deal — val­ued at $4.2 bil­lion to­tal — was just as much about the ap­proved in­di­ca­tion of prostate can­cer as the two women’s health con­di­tions the drug could treat.

A month lat­er, the two com­pa­nies are of­fer­ing an­oth­er glimpse of the ther­a­py’s longterm po­ten­tial in en­dometrio­sis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN